'Global pharmacovigilance spending will be worth $15.46bn by 2015' says visiongain analyst

A new report by visiongain, a London-based business information company, predicts that global pharmacovigilance spending will be worth $15.46bn by 2015. The market was worth just under $12bn in 2010.
Spread the Word
Listed Under

* Pharmaceutical
* Conctract
* Api
* Cmo
* R D
* US
* Kemwell
* Qbd
* Gmp
* Scm Pharma

* Medical
* Health
* Business

* London City - London, Greater - England

Sept. 7, 2011 - PRLog -- Pharmacovigilance has evolved rapidly over the past three decades. The monitoring of drug safety standards is now overseen by a number of regulatory authorities. With the increasing cost of getting a drug to market (now estimated to be $800m to $1bn), pharmaceutical companies cannot afford to have a drug recalled because of severe adverse events. The damage to brand reputation may also be irreparable.

Dr Sharmarke Mohamed, healthcare industry analyst, says: "Pharmacovigilance is now at a stage where regulatory authorities are starting to understand the importance of having greater consumer participation in the reporting of adverse drug reactions (ADRs). This has been mandated in the new EU legislation on pharmacovigilance. There is still significant work to be done, however, in improving pharmacovigilance standards across different countries. Despite the efforts of the ICH, there are still considerable discrepancies in how the recommendations of the ICH are interpreted across different countries. This is a significant market restraint."

Visiongain predicts that this market will grow steadily to 2021. The future of the pharmacovigilance market looks promising. This new report adds to visiongain's wide range of analytical reports in healthcare and other industries.

To see sample pages of this report please visit http://www.visiongain.com/Report/674/Pharmacovigilance-an...

For an exec summary please email Sara Peerun
Email: sara.peerun@visiongainglobal.com
Tel: +44 2027 3366100


Notes jfmnr for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

# # #

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Email:***@visiongain.com Email Verified
Phone:+44 020 7336 6100
Zip:EC1V 2QY
Tags:Pharmaceutical, Conctract, Api, Cmo, R D, US, Kemwell, Qbd, Gmp, Scm Pharma
Industry:Medical, Health, Business
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share